Healthcare provider profile · identity verified

Brian Scheeringa, MD

Allopathic & Osteopathic Physicians|Family Medicine · GRANDVILLE, MI · NPI 1245473784

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Brian Scheeringa, MD received $134.71 in general payments during 2025 across 1 reported records.

Stryker Corporation accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$134.71

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Stryker Corporation Unresolved — no canonical attribution shown $134.71100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$134.711

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
CLOTTRIEVER BOLD CATHETER
Normalized: clottriever bold catheter
Device Stryker Corporation $134.71 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium483138
LisinoprilLisinopril355106
Amlodipine BesylateAmlodipine Besylate28180
Metformin HclMetformin Hcl17147
Levothyroxine SodiumLevothyroxine Sodium16343
Losartan PotassiumLosartan Potassium14240
Tamsulosin HclTamsulosin Hcl14245
SimvastatinSimvastatin13941
OmeprazoleOmeprazole13340
Metoprolol SuccinateMetoprolol Succinate12941
HydrochlorothiazideHydrochlorothiazide12031
Pravastatin SodiumPravastatin Sodium9424
Trazodone HclTrazodone Hcl8326
Pioglitazone HclPioglitazone Hcl7325
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide6718
Cyclobenzaprine HclCyclobenzaprine Hcl6132
Metformin Hcl ErMetformin Hcl6015
Metoprolol TartrateMetoprolol Tartrate6018
AllopurinolAllopurinol5716
GabapentinGabapentin5718
Buspirone HclBuspirone Hcl5314
CarvedilolCarvedilol5315
GlipizideGlipizide5213
EliquisApixaban4915
Zolpidem TartrateZolpidem Tartrate49suppressed
Rosuvastatin CalciumRosuvastatin Calcium4718
Fluticasone PropionateFluticasone Propionate4515
Pantoprazole SodiumPantoprazole Sodium4414
Albuterol Sulfate HfaAlbuterol Sulfate4318
Citalopram HbrCitalopram Hydrobromide4313
Sertraline HclSertraline Hcl3715
AlprazolamAlprazolam35suppressed
AtenololAtenolol3412
FamotidineFamotidine31suppressed
GlimepirideGlimepiride30suppressed
JanuviaSitagliptin Phosphate30suppressed
PrednisonePrednisone3026
Escitalopram OxalateEscitalopram Oxalate29suppressed
FarxigaDapagliflozin Propanediol28suppressed
Glipizide ErGlipizide28suppressed
LorazepamLorazepam28suppressed
Fluoxetine HclFluoxetine Hcl27suppressed
MeloxicamMeloxicam26suppressed
MounjaroTirzepatide24suppressed
TrulicityDulaglutide24suppressed
FinasterideFinasteride22suppressed
SpironolactoneSpironolactone22suppressed
Bupropion XlBupropion Hcl21suppressed
Hydroxyzine HclHydroxyzine Hcl21suppressed
Warfarin SodiumWarfarin Sodium21suppressed
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20suppressed
CephalexinCephalexin1918
FurosemideFurosemide19suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19suppressed
Tramadol HclTramadol Hcl19suppressed
Alendronate SodiumAlendronate Sodium18suppressed
Isosorbide Mononitrate ErIsosorbide Mononitrate18suppressed
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide17suppressed
Diltiazem 24hr Er (Cd)Diltiazem Hcl16suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16suppressed
Hydralazine HclHydralazine Hcl16suppressed
Montelukast SodiumMontelukast Sodium16suppressed
Oxybutynin ChlorideOxybutynin Chloride16suppressed
OzempicSemaglutide16suppressed
Potassium ChloridePotassium Chloride16suppressed
Sildenafil CitrateSildenafil Citrate16suppressed
Diclofenac SodiumDiclofenac Sodium15suppressed
NystatinNystatin15suppressed
Duloxetine HclDuloxetine Hcl14suppressed
PregabalinPregabalin14suppressed
Triamcinolone AcetonideTriamcinolone Acetonide1411
Venlafaxine Hcl ErVenlafaxine Hcl14suppressed
XareltoRivaroxaban14suppressed
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril13suppressed
ChlorthalidoneChlorthalidone13suppressed
Doxazosin MesylateDoxazosin Mesylate13suppressed
FentanylFentanyl13suppressed
MirtazapineMirtazapine13suppressed
Morphine Sulfate ErMorphine Sulfate13suppressed
Testosterone CypionateTestosterone Cypionate13suppressed
ValsartanValsartan13suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav1211
ClonazepamClonazepam12suppressed
EszopicloneEszopiclone12suppressed
LovastatinLovastatin12suppressed
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11suppressed
MethocarbamolMethocarbamol11suppressed
Tizanidine HclTizanidine Hcl11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $134.71 · 1 records Stryker Corporation CLOTTRIEVER BOLD CATHETER
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error